Chief Executive Officer
John P. McLaughlin has served as our Chief Executive Officer since December 2008, when the Company spun-off Facet Biotech Corporation (Facet Biotech). From December 2008 until September 2017, Mr. McLaughlin served the Company as both President and Chief Executive Officer.
Mr. McLaughlin was elected a director of the Company in October 2008 and from November 6, 2008 until the spin-off on December 18, 2008, he served as a Senior Advisor to the Company. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr. McLaughlin served as counsel to various subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws.
Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc. He also co-founded and served as a director of Peak Surgical, Inc., a privately-held medical device company subsequently purchased by Medtronic, Inc. He also served as a director of AxoGen, Inc., Adverum Biotechnologies, Inc. and Seattle Genetics, publicly-traded biopharmaceutical companies. He received a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America. Mr. McLaughlin possesses a strong understanding of the biotechnology industry and has experience in development, regulation and commercialization of drugs, corporate licensing and litigation that the Company values. In addition, Mr. McLaughlin provides strategic guidance to our management team and the Board.
Dominique Monnet, our President, joined the Company in September 2017. Before joining PDL, Mr. Monnet served as senior vice president and chief marketing officer of Alexion Pharmaceuticals in 2014 to 2015 where he was responsible for commercial operations in the U.S. and Latin America and oversaw new products and global business operations functions.
From 2002 to 2013, he was a senior executive at Amgen Inc. where he served in a number of key commercial leadership positions in the U.S. and internationally. As vice president and general manager for Amgen’s Inflammation Business Unit in 2011 to 2013, he was responsible for accelerating the growth of the Enbrel® franchise in the highly competitive U.S. market. Prior to this, he served as vice president and head of Amgen’s Global Marketing and Commercial Development, where he led the marketing strategies and global launches of new products across a range of therapeutic areas.
From 2002 through 2006, Mr. Monnet was based in Zug, Switzerland, where he served as Amgen’s vice president of International Marketing and Business Operations, building Amgen’s international commercial capability and leading the creation of its successful international franchises in oncology and nephrology. Before joining Amgen, Mr. Monnet held positions of increasing responsibility in line commercial management and global marketing over 19 years at Schering-Plough – including General Manager of its affiliate in the UK and Republic of Ireland — Ciba-Geigy and Alza Corporation. Mr. Monnet holds a business degree from EDHEC Business School in Lille, France, and an MBA from INSEAD in Fontainebleau, France.
Vice President and Chief Financial Officer
Peter Garcia, our Vice President and Chief Financial Officer, joined the Company in May, 2013. Before joining PDL, Mr. Garcia served as CFO of BioTime, Inc., which he joined in 2011. Between the years of 1996 and 2011, Mr. Garcia was CFO of six biotech and high-tech companies, including Marina Biotech, Nanosys, Nuvelo, Novacept, IntraBiotics Pharmaceuticals and Dendreon Corporation.
While at these companies, he raised over $550 million, led multiple merger and acquisition transactions, and managed multiple functions including finance, accounting, treasury, investor relations, corporate communications, IT and facilities. From 1990 to 1996, he was a finance executive with Amgen. Mr. Garcia holds a B.A. in economics and sociology with honors from Stanford University and an MBA with an emphasis in finance and accounting from UCLA.
Vice President and General Counsel
Christopher Stone, our Vice President, General Counsel and Secretary, joined the Company in February 2009. He brings more than 27 years of legal experience to the role. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection, research collaborations and licensing.
Prior to that time, he was Vice President of Intellectual Assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994 to 2005, Mr. Stone was with Genencor International, a biotechnology company which was acquired by Danisco in 2005, most recently as Vice President of Intellectual Property and General Patent Counsel. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications, intellectual property transactions including licensing and research collaboration management, and managed multiple litigation and interference proceedings and numerous European patent oppositions.
Mr. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is an active member of the District of Columbia Bar, Nevada Bar and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992
Jill Jene, Ph.D.
Vice President, Business Development
Jill Jene, Ph.D., our Vice President, Business Development, joined the Company in May, 2018. Dr. Jene brings to PDL more than 20 years of biopharmaceutical business development experience that includes more than $3 billion in licensing and M&A transactions. Prior to PDL, she served as Senior Vice President, Business Development at twoXAR.
Previously, she was with Depomed from 2006 to 2017, rising to the position of Vice President, Business Development. At Depomed, she was instrumental in closing more than 20 transactions including the acquisition of four commercial franchises. Earlier in her career, Dr. Jene held positions of increasing responsibilities in business development at Cell Genesys, 3M Company and Baxter International. Dr. Jene holds a Ph.D. and M.S. in chemistry from Northwestern University, an MBA from DePaul University and a B.S. in chemistry from Bradley University.
Deputy General Counsel
Nathan Kryszak, our Deputy General Counsel and Assistant Secretary joined the Company in August 2014 as Senior Counsel. Since joining the Company, Mr. Kryszak was appointed Assistant Secretary in September 2014 and promoted to Deputy General Counsel effective January 2017.
Harold Selick, Ph.D.
Dr. Selick joined the PDL BioPharma Board of Directors in August 2009. Dr. Selick serves as Vice Chancellor of Innovation and Partnerships at the University of California, San Francisco, where he oversees proof-of-concept studies of promising UCSF life science inventions, including drug molecules, device prototypes and digital health applications. Dr. Selick serves as Chair of the Board of Molecular Templates, which merged with Threshold Pharmaceuticals, Inc. in 2017, where he was Chief Executive Officer and Director from 2002 to 2017.
Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc. from 2002 to 2007 and Chief Executive Officer of the biotech company, Camitro Corporation, from 1999 to 2002. From 1999 to 2002, he was with Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, serving most recently as Vice President of Research. Prior to Affymax, Dr. Selick held scientific positions at Anergen, Inc. and Protein Design Labs, Inc. (now PDL BioPharma, Inc.), where he co-invented technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.A. and Ph.D. degrees from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.
Dr. Selick brings to the PDL BioPharma Board of Directors a scientific perspective as well as operational experience derived from his role as Chief Executive Officer of a publicly traded biotechnology company. In addition to Lead Director, he is Chair of the Compensation Committee and Chair of the Nominating and Governance Committee.
Mr. Edick joined the PDL BioPharma Board of Directors in September 2015. Mr. Edick has more than 35 years of experience in the life sciences industry. In 2017, he was appointed President and Chief Executive Officer of the specialty pharmaceuticals company Xeris Pharmaceuticals, Inc., where he also serves as a Director.
Prior to Xeris, Mr. Edick was Managing Partner of 3G Advisors, LLC., a consultancy to the pharmaceutical, healthcare and healthcare investor communities. He served as Chief Executive Officer for Durata Therapeutics, Inc., from 2010 to 2014, Ganic Pharmaceuticals, Inc., from 2008 to 2010, and MedPointe Healthcare, Inc., from 2002 to 2008. Prior to that, he held senior executive positions at GD Searle & Company and Pharmacia Corporation. Mr. Edick holds a B.A. in Psychology from Hamilton College.
In addition to Xeris, Mr. Edick serves on the Boards of Directors for Sucampo Pharmaceuticals Inc., NewLink Genetics Corporation, Neos Therapeutics, Inc., and Amerita, Inc.
Mr. Edick brings to the PDL BioPharma Board of Directors extensive experience in the development and commercialization of biotechnology products. He is a member of the Audit Committee and Litigation Committee.
Mr. Gryska joined the PDL BioPharma Board of Directors in March 2014. Mr. Gryska has more than 30 years of financial experience, primarily in the biopharmaceuticals industry. He has served as Executive Vice President and Chief Financial Officer for Incyte Corporation since 2014.
Prior to Incyte, he was Chief Financial Officer of Celgene Corporation from 2006 to 2010 and Principal at Strategic Consulting Group, a consultancy to early-stage biotechnology companies, from 2004 to 2006. He held the position of Chief Financial Officer of Scios Inc., from 1998 to 2004 and Cardiac Pathways from 1993 to 1998. Prior to Cardiac Pathways, Mr. Gryska was an audit partner at Ernst & Young for 11 years, where he focused primarily on the biotechnology and healthcare industries. He holds a B.A. in Accounting and Finance from Loyola University and an MBA from Golden Gate University.
Mr. Gryska serves on the Board of Directors of Seattle Genetics and Aerie Pharmaceuticals, Inc.
Mr. Gryska brings to the PDL BioPharma Board of Directors extensive knowledge of, and experience in, the application of accounting principles and the financial reporting process. He is a member of the Audit Committee and Nominating and Governance Committee.
Ms. Lindell joined the PDL BioPharma Board of Directors in March 2009. Since 2000, she has served as President and Chief Executive Officer of S.G. Management, Inc., an asset management company. Prior to that, Ms. Lindell served for 25 years at KPMG LLP, during which she was an audit partner for 16 years.
Most recently at KPMG, she was Partner-In-Charge of the Industrial Markets and Healthcare and Life Sciences practices for the Western Area. She holds a B.A. from Stanford University and an MBA from the Stanford Graduate School of Business.
Ms. Lindell serves on the Board of Directors of The Cooper Companies and is Chair of its Audit Committee and a member of its Organization and Compensation Committee. She also serves on the Advisory Board and Advisors Loan Committee for First Republic Bank.
Ms. Lindell brings to the PDL BioPharma Board of Directors extensive accounting experience, including knowledge of accounting principles, financial reporting rules and regulations, and the financial reporting process. She is Chair of the Audit Committee and is a member of the Nominating and Governance Committee and Compensation Committee.
Mr. McLaughlin joined the PDL BioPharma Board of Directors in October 2008. Mr. McLaughlin has served as Chief Executive Officer of PDL BioPharma since 2008, and was the Company’s President from 2008 to 2017.
Prior to joining PDL, he was Chief Executive Officer and Director of Anesiva, Inc., (formerly as Corgentech, Inc.) from 2000 to 2008 and President of Tularik, Inc., from 1997 to 1999. Prior to that, Mr. McLaughlin held various senior management positions at Genentech, Inc., from 1987 to 1997, including Executive Vice President and General Counsel. From 1985 to 1987, Mr. McLaughlin was a partner at a Washington, D.C.-based law firm specializing in food and drug law. Previously, Mr. McLaughlin served as counsel to various subcommittees of the United States House of Representatives, where he drafted numerous measures that became FDA laws. He holds a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America.
Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., and co-founded and served as Director of Peak Surgical, Inc., with both firms subsequently acquired by OSI Pharmaceuticals and Medtronic, respectively. He previously served as a Director of AxoGen, Inc., Adverum Biotechnologies, Inc. and Seattle Genetics, Inc.
Mr. McLaughlin brings the Board of Directors of PDL BioPharma a strong understanding of the biotechnology industry and experience in the development, regulation and commercialization of drugs, as well as corporate licensing and litigation. He is a member of the Litigation Committee.
Ms. O’Farrell joined the PDL BioPharma Board of Directors in June 2018. Ms. O’Farrell previously served 24 years with Eli Lilly and Company, most recently as Chief Procurement Officer from 2012 to 2017.
At Eli Lilly, she advanced through various executive management positions, including Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O’Farrell was an accountant with Boise Cascade Office Products and auditor at Whipple & Company and Price Waterhouse. Ms. O’Farrell holds a BS in accounting with honors and an MBA in management information systems, both from Indiana University.
Ms. O’Farrell served as a Board member of the YMCA of Greater Indianapolis for more than a decade and as its Chair from 2014 to 2016. She is a member of the Finance Committee of the United Way of Brevard, in Brevard County, FL., and previously served on the Boards of the Washington Township Schools Foundation and Keep Indianapolis Beautiful.
Ms. O’Farrell brings to the PDL Board of Directors extensive experience as a senior executive of a major pharmaceutical company with global operations. She is a member of the Audit Committee.
Dr. Samuel Saks
Dr. Saks joined the PDL Board of Directors in September 2015. Dr. Saks is a board-certified oncologist. He served as Chief Development Officer and Director for Auspex Pharmaceuticals, Inc., from 2013 to 2015, at which time that firm was acquired by Teva Pharmaceuticals Industries ltd.
Prior to Auspex, Dr. Saks was Chief Executive Officer for six years of Jazz Pharmaceuticals plc., a firm he co-founded. Before that, Dr. Saks served as Company Group Chairman of ALZA Corp., and then participated as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee upon the merger of Johnson & Johnson and ALZA. Prior to ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough Corporation, Xoma Corp. and Genentech, Inc. Dr. Saks holds a B.S. in Biology and an M.D. from the University of Illinois.
Dr. Saks serves on the Board of Directors of TONIX Pharmaceuticals Holding Corp., Bullet Biotechnology, Inc., Velocity Pharmaceutical Development, LLC., and NuMedii Inc.
Dr. Saks brings to the PDL Board of Directors more than 35 years of experience in biotechnology management, including extensive product development expertise. He is a member of the Compensation Committee.
Mr. Sandman joined the PDL BioPharma Board of Directors in October 2008. Mr. Sandman held various senior management positions at Boston Scientific Corporation from 1993 to 2008, most recently as Executive Vice President, Secretary and General Counsel.
From 1984 to 1993, he served at Wang Laboratories, Inc., ending his tenure there as Senior Vice President, General Counsel and Secretary. Mr. Sandman received his A.B. from Boston College and his J.D. from Harvard Law School.
Mr. Sandman is a member of the Business Advisory Board of NuVascular Technologies.
Mr. Sandman brings to the PDL BioPharma Board of Directors more than 30 years of experience as a general counsel and executive officer of a major, publicly traded medical technology company. He has extensive knowledge of corporate governance and experience in intellectual property litigation. He is the chair of the Litigation Committee.
Mr. Yanai joined the PDL BioPharma Board of Directors in June 2018. Mr. Yanai serves as Chairman of the Board of biopharmaceutical companies Cambrex Corporation and Protalix BioTherapeutics, Inc. He served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 to 2012, and thereafter as an advisor to the company through 2015.
Previously, he was President and Chief Executive Officer of ADAMA Agricultural Solutions (formerly Makhteshim Agan Industries), a global agricultural chemicals company. Mr. Yanai retired in 2001 after a 32-year career in the Israeli Army with the rank of Major General. Mr. Yanai holds a BS in political science and economics from Tel Aviv University, an MPA in national resources management from George Washington University, and is a graduate of the Advanced Management Program of Harvard Business School and the U.S. National War College in the National Defense University.
Mr. Yanai serves as a member of the Board of Governors of the Technion-Israel Institute of Technology of Haifa, Israel, and the Board of Trustees of Bar-Ilan University–Israel. He previously served as Director of Lumenis Ltd., Sagent Pharmaceuticals, Perrigo Company plc and Quinpario Acquisition Corp.
Mr. Yanai brings to the PDL BioPharma Board of Directors global operating and leadership experience in the life science and pharmaceutical industries, including as a senior executive and board member of public and private companies.